Procter & Gamble
This article was originally published in The Rose Sheet
Executive Summary
Company confirms its sales and earnings guidance for the second quarter of fiscal year 2007, projecting sales growth of 5%-8% and organic sales growth of 4%-7%. The company will announce final results for the quarter Jan. 30, 2007. Q1 revenue increased 11% to $5.6 bil. due to growth across all categories, P&G said during Dec. 14 analyst call. Organic sales volume in the skin care division was up double digits, driven by the launch of Olay Definity and the performance of OlayRegenerist (1"The Rose Sheet" Nov. 6, 2006, p. 8)...
You may also be interested in...
P&G Q1 Beauty Sales Advance On Performance Of Olay, Pantene
Procter & Gamble beauty division revenues increased 11% to $5.6 bil. for the first quarter of fiscal year 2007 (ended Sept. 30), fueled by growth across all categories and the addition of Gillette products, the company reported in an Oct. 31 earnings release
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.